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SUMMARY
Twist1 and Twist2 are major regulators of embryogenesis. Twist1 has been shown to favor the metastatic dis-
semination of cancer cells through its ability to induce an epithelial-mesenchymal transition (EMT). Here, we
show that a large fraction of human cancers overexpress Twist1 and/or Twist2. Both proteins override onco-
gene-induced premature senescence by abrogating key regulators of the p53- and Rb-dependent pathways.
Twist1 and Twist2 cooperate with Ras to transform mouse embryonic fibroblasts. Interestingly, in epithelial
cells, the oncogenic cooperation between Twist proteins and activated mitogenic oncoproteins, such as Ras
or ErbB2, leads to complete EMT. These findings suggest an unanticipated direct link between early escape
from failsafe programs and the acquisition of invasive features by cancer cells.INTRODUCTION
Twist proteins are highly conserved basic helix-loop-helix
(bHLH) transcription factors that have important regulatory func-
tions during embryogenesis. In Drosophila, the ancestral Twist
protein (named DTwist) is crucial for proper gastrulation and
mesoderm formation (Simpson, 1983; Thisse et al., 1987). In
mammals, two Twist-like proteins, Twist1 and Twist2, share
high structural homology (Li et al., 1995; Wolf et al., 1991).
Gene deletion experiments have shown that TWIST1 is required
for closure of the neural tube during mouse development (Chen
and Behringer, 1995), while TWIST2 knockout mice display ele-
vated expression of proinflammatory cytokines causing perinataldeath (Sosic et al., 2003). Interestingly, this phenotype is also
found in individuals doubly heterozygous for TWIST1 and
TWIST2 alleles, reflecting some functional redundancy (Bialek
et al., 2004). While Twist proteins are only expressed in a subset
of mesodermally and ectodermally derived tissues, TWIST1 is
overexpressed in various human solid tumors including numer-
ous types of carcinomas as well as sarcomas, gliomas, neuro-
blastomas, and melanomas (Yang et al., 2004; Kwok et al.,
2005; Mironchik et al., 2005; Zhang et al., 2007; Ohuchida
et al., 2007; Entz-Werle et al., 2005; Elias et al., 2005; Valsesia-
Wittmann et al., 2004; Hoek et al., 2004). The role of Twist1 in
tumor progression has been convincingly associated with the
metastatic process (Yang et al., 2004). Exogenous overexpressionSIGNIFICANCE
Because cells are frequently subjected to abnormal growth signals, multicellular organisms develop two major safeguard
programs, senescence and apoptosis, that can eliminate potentially deleterious cells at early stages of tumor development.
The mechanisms by which precancer cells escape these protective barriers remain to be determined. Herein, we identify
Twist proteins as decisive early drivers of tumorigenesis. Indeed, Twist1 and Twist2 abrogated oncogene-induced senes-
cence by inhibiting key regulators of this safeguard program. Strikingly, this deleterious effect was associated with com-
plete epithelial-mesenchymal transition (EMT), a process associated with the acquisition of invasive potential. These obser-
vations suggest that some metastatic capabilities of cancer cells can be acquired during malignant conversion as a side
effect of the inactivation of primary failsafe mechanisms.Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc. 79
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man cancer cells by promoting the downregulation of E-cadherin
and the induction of an epithelial-mesenchymal transition (EMT)
(Yang et al., 2004; Kwok et al., 2005; Mironchik et al., 2005).
EMT, which was first recognized as a feature of embryogenesis,
converts epithelial cells into mesenchymal cells and promotes
cell motility through profound disruption of cell-cell junctions
and extensive reorganization of the actin cytoskeleton (Hay,
1995).
The results presented herein indicate that TWIST2, similarly to
TWIST1, is overexpressed in a large variety of human primary
tumors and cancer cell lines. We next demonstrate that both
Twist1 and Twist2 inhibit premature senescence in cancer cells,
a process identified as an initial barrier to tumor development.
Indeed, senescence occurs in vivo in precancerous lesions in
response to aberrant mitogenic signaling, and its inactivation is
required for progression toward malignancy (Chen et al., 2005;
Michaloglou et al., 2005; Collado et al., 2005). We further show
that this property allows Twist proteins to cooperate with mito-
genic oncoproteins, resulting in full transformation of murine
cells. Interestingly, in human epithelial cells, escape from prema-
ture senescence mediated by Twist1 or Twist2 is associated with
complete EMT. Altogether, these findings suggest an as yet un-
described link between early escape from failsafe programs and
acquisition of metastatic features.
RESULTS
Twist1 and Twist2 Override Oncogene-Induced
Senescence in Murine and Human Cancer Cells
Twist1 has been shown to play a major role in breast cancer pro-
gression by promoting EMT and favoring the metastatic process
(Yang et al., 2004). To further evaluate the role of both Twist pro-
teins in carcinoma progression, we first took advantage of the
MMTV-ErbB2/Neu transgenic mouse model (unactivated rat
ErbB2/Neu gene under the transcriptional control of the mouse
mammary tumor virus promoter/enhancer). ERBB2 is a major
oncogene involved in human breast tumorigenesis, and this
mouse model is considered to be an appropriate tool for deci-
phering the molecular pathways involved in breast cancer pro-
gression. After a long latency, which is believed to represent
the time required for mammary epithelial cells to acquire addi-
tional cooperative events, MMTV-ErbB2/Neu transgenic mice
stochastically develop focal mammary tumors that can eventu-
ally metastasize to the lungs (Guy et al., 1992). Analysis of
TWIST1 and TWIST2 expression in twenty independent sponta-
neous mammary tumors demonstrated a frequent activation of
the TWIST2 gene (Figure 1). Indeed, whereas TWIST1 expres-
sion levels remained weak in all tumors, TWIST2 was signifi-
cantly upregulated (p < 0.0001) in 12 of them (60%), suggesting
that Twist2 might be involved in tumor progression.
In an initial approach to define potential Twist2 oncogenic
functions, cancer cell lines derived from either TWIST2-positive
or -negative tumors from MMTV-ErbB2/Neu transgenic mice
were established, and the consequences of TWIST2 depletion
by RNA interference were evaluated. Surprisingly, knockdown
of TWIST2 in TWIST2-expressing cell lines invariably triggered
cellular senescence characterized by flattened cytoplasm,
G1 growth arrest, senescence-associated b-galactosidase80 Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc.(SA-b-gal) activity, and induction of the de novo marker of cellu-
lar senescence DEC1 (Qian et al., 2008; Collado et al., 2005)
(Figure 2). Similar results were obtained using two independent
TWIST2 shRNA sequences. As expected, these two shRNAs
had no effect on TWIST2-negative cell lines, thus demonstrating
the specificity of the observation.
As aberrant activation of ErbB2 in mammary epithelial cells
triggers a premature senescence response (Trost et al., 2005),
our observations suggested that Twist2 induction might override
oncogene-induced senescence in vivo. This property was not
limited to murine cells. In fact, TWIST2 but also TWIST1 deple-
tion promoted senescence in human melanoma and breast
cancer cell lines (Figure 3), linking Twist1 and Twist2 to the
inactivation of this failsafe program.
TWIST1 and TWIST2 Are Frequently Overexpressed
in Human Cancers
Whereas the overexpression of TWIST1 has already been de-
scribed in a large variety of tumors, the status of TWIST2 in ma-
lignancies remains largely unknown. We thus measured TWIST1
and TWIST2 mRNA levels in a wide range of human tumors (n =
148) and human tumor-derived cell lines (n = 64) encompassing
eight different cancer types (Figure 4A; see also Figure S1 avail-
able online). Overall, TWIST1 and TWIST2 were significantly up-
regulated in primary tumor cells (p = 0.002 and p = 0.04, respec-
tively) and in cancer cell lines (p < 0.0001 and p = 0.0042,
respectively) compared to their normal counterparts. As shown
in Figure 4A, TWIST1 and TWIST2 overexpression was particu-
larly frequent in melanoma samples. Melanomas are malignant
proliferation of cutaneous melanocytes that can develop from
benign nevi. Premature senescence is a major safeguard mech-
anism preventing the progression from nevi to melanomas
(Michaloglou et al., 2005). Although generally harboring activat-
ing mutations in the B-Raf oncoprotein (a major effector of
Ras), nevi typically remain in a growth-arrested state for de-
cades. Peeper and collaborators have demonstrated that cells
within nevi display characteristic features of senescence (includ-
ing expression of p16Ink4a) and are growth arrested, whereas in
Figure 1. TWIST2 Is Overexpressed in MMTV-ErbB2/Neu-Derived
Mammary Tumors
TWIST1 and TWIST2 gene expression in spontaneous tumors developed in
MMTV-ErbB2/Neu transgenic mice as assessed by quantitative RT-PCR. Error
bars represent mean ± SD of triplicate experiments.
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Inhibition of Premature Senescence by Twistmelanoma, senescence is absent and cells proliferate (Michalo-
glou et al., 2005). Based on these observations, we evaluated
Twist1 and p16Ink4a expression using immunohistochemistry in
a series of 12 melanocytic nevi and 10 melanomas. (Of note,
Figure 2. TWIST2 Depletion Induces Senes-
cence in MMTV-ErbB2/Neu-Derived Tumor
Cells
Cells derived from MMTV-ErbB2/Neu transgenic
mouse tumors either overexpressing TWIST2 (tu-
mor 7-derived cell line, [A]) or with no endogenous
expression of TWIST2 (tumor 2-derived cell line,
[B]) were transiently infected with retroviral con-
structs expressing either shRNAs directed against
the murine TWIST2 gene (shRNA mTWIST2 A and
shRNA mTWIST2 B) or shRNAs directed against
the luciferase gene (shRNA LUC) or the prion
pRpC protein (shRNA PRPC) as controls.
Upper panels: representative photomicrographs
of cells obtained by phase-contrast microscopy
and of SA-b-galactosidase staining observed in
bright field.
Lower panels: TWIST1 and TWIST2 expression
levels as assessed by real-time quantitative RT-
PCR (qPCR; relative mRNA levels are indicated),
% of increase in G1-arrested cells, % of SA-
b-galactosidase (SA-b-Gal)-positive cells, and
fold induction of the senescence marker DEC1
are shown. Error bars represent mean ± SD of
triplicate experiments.
there is no reliable antibody against
Twist2 currently available.) Strikingly, all
nevi contained p16Ink4a-expressing cells
(50%–100% positive cells in 8 out of 12
cases), whereas no Twist1-expressing
cells were observed. In contrast, high
levels of Twist1 were detected in 5 out
of 10 cases of melanoma. Consistent
with a role of Twist1 in the inhibition of
premature senescence, p16Ink4a immu-
noreactivity was either undetectable or
low in these samples, with an exclusive
pattern when compared with Twist1
immunoreactivity (Figure 4B).
Twist1 and Twist2 Cooperate with
Activated Ras for Malignant
Transformation and Disrupt Both
p53 and Rb Tumor Suppressor
Pathways
The induction of premature senescence
following constitutive activation of the
Ras/Raf mitogenic pathway is particularly
well documented (Serrano et al., 1997).
To further study the biological effects of
Twist1 and Twist2, standard cooperation
assays were performed in primary murine
embryonic fibroblasts (MEFs) using an
activated form of H-Ras (H-RasV12).
As expected, MEFs infected only with
H-RasV12 immediately stopped growing and underwent senes-
cence characterized by flattened cytoplasm, induction of
SA-b-gal activity, and G1 growth arrest (data not shown). In con-
trast, cells sequentially infected with H-RasV12 and either Twist1Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc. 81
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maintained in culture for months. MEFs overexpressing both
H-RasV12 and Twist1 or Twist2 exhibited hallmarks of malignant
Figure 3. TWIST1 and/or TWIST2 Depletion Induces
Senescence in Human Breast Cancer and Melanoma
Cell Lines
T47D (human breast cancer cell line carrying four copies of
ERBB2; [A]) and RPMI 7951 (human melanoma cell line carry-
ing a mutant B-RafV600E; [B]) cells were doubly infected with
lentiviral constructs expressing either shRNA directed against
the human TWIST1 (shRNA hTWIST1 A and shRNA hTWIST1
B) or TWIST2 (shRNA hTWIST2 A and shRNA hTWIST2 B)
genes as indicated or shRNAs directed against the luciferase
gene (shRNA LUC) or the prion pRpC protein (shRNA PRPC)
as controls.
Upper panels: representative photomicrographs of cells ob-
tained by phase-contrast microscopy and of SA-b-galactosi-
dase staining observed in bright field.
Lower panels: TWIST1 and TWIST2 expression levels as
assessed by real-time qPCR (relative mRNA levels are
indicated), % of increase in G1-arrested cells, and % of SA-
b-Gal-positive cells are shown. Error bars represent mean ±
SD of triplicate experiments.
transformation such as loss of contact inhibition,
growth in soft agar, and high tumorigenic potential
as demonstrated after subcutaneous grafting into
athymic nude mice (Figures 5B–5D; Figure S2). Al-
though the time required for tumor growth varied
slightly, clonogenic and tumorigenic capabilities
were observed even in the presence of relatively
low levels of ectopic Ras and/or Twist expression
(data not shown). Upon histological examination,
expanding xenografts displayed all of the features
of aggressive sarcomas, with high levels of aber-
rant mitosis, anisokaryosis, and major angiogenic
activity, further demonstrating a potent oncogenic
cooperation between Twist proteins and Ras
(Figure 5). Of note, although Twist proteins have
been shown to regulate proinflammatory cytokine
gene expression (Sosic et al., 2003), microarray
analysis of MEFs and transformed MEFs did not
show striking differences in expression of chemo-
kines, interleukins, and their receptors (Table S1).
The p53 and Rb tumor suppressor pathways are
known to play a pivotal role in the onset of prema-
ture senescence (Serrano et al., 1996). To further
investigate the mechanisms by which Twist pro-
teins inhibit oncogene-induced failsafe programs,
we compared the endogenous expression of
p16Ink4a, ARF, p53, and p21Cip1 in MEFs infected
with H-RasV12 alone or in combination with Twist1
or Twist2 retroviral expression constructs. As
shown in Figure 6A, Twist1 or Twist2 expression
was sufficient to completely abrogate p16Ink4a
and p21Cip1 induction by activated Ras without
downregulating ARF and p53 levels. Identical inhib-
itory effects were observed in cell lines either gen-
erated through the MEF transformation assays
(Ras + Twist1, Ras + Twist2) or derived from tumors induced in
athymic nude mice (Figure 6A). To confirm that Twist per se
was sufficient to abrogate p16Ink4A and p21Cip1 activation, we82 Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc.
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Ras + Twist1-transformed MEFs. As shown in Figure 6B, inhibi-
tion of TWIST1 expression led to a significant reinduction of the
expression of both cyclin-dependent kinase inhibitors. Never-
theless, this reinduction was not sufficient to trigger senescence,
which might be due to residual ectopic Twist1. To gain insight
into the mechanisms underlying the regulatory roles of Twist pro-
teins, the effect of Twist1 and Twist2 on the p16INK4A and
p21CIP1 genes was assessed in reporter assays. Consistent
with the protein expression profile observed, Twist1 and Twist2
inhibited p16INK4A and p21CIP1 promoter activation by H-RasV12
and p53 (Figures 6C and 6D). Although the molecular mecha-
nisms involved in this effect are still under investigation, prelim-
inary experiments suggest that the ability of Twist proteins to
prevent the Ras-mediated activation of p16INK4A might be asso-
ciated with their ability to interact with the Ras effector Ets2
(Figure S3).
Twist1 and Twist2 Overcome Premature Senescence
and Cooperate Further with Mitogenic Oncoproteins
to Promote EMT and Invasiveness
The ability of Twist1 and Twist2 to overcome oncogene-induced
senescence was confirmed in a variety of human cells including
primary mammary epithelial cells (HMECs) (Figure 7), IMR90 and
MRC5 diploid fibroblasts (Figure S4), and immortalized BJ pri-
mary fibroblasts expressing an inducible version of H-RasV12
(data not shown). In all cases, expression of Twist1 or Twist2
completely abolished premature senescence induced by the ac-
tivated mitogenic oncoprotein. We thereby confirmed that
Twist1 or Twist2 overexpression was sufficient to override this
crucial primary safeguard mechanism, thus providing a rationale
for the observed oncogenic cooperation. Intriguingly, experi-
ments with HMECs revealed a second level of cooperation. As
Figure 4. TWIST1 and TWIST2 Genes Are Overexpressed in Various
Human Tumors and Tumor-Derived Cell Lines
(A) TWIST1 and TWIST2 gene expression was assessed by TaqMan real-time
quantitative PCR analysis. Expression was compared with that of healthy tis-
sue or normal cell counterparts. Percentages of samples harboring an overex-
pression of TWIST1 or TWIST2 genes (>2-fold) are shown. (More information is
available in Figure S1 and the Supplemental Experimental Procedures.) ESCC,
esophageal squamous cell carcinoma; CLL, chronic lymphoid leukemia; HCC,
hepatocellular carcinoma.
(B) Immunohistochemical analysis of p16Ink4a and Twist1 protein levels in hu-
man nevi and melanomas. Brownish dots detected in the cytoplasm of nevus
cells are melanin granules. The dark brown cells in nevi are fibroblasts reveal-
ing that dermal fibroblasts are reactive for Twist1.
Figure 5. Twist Proteins Cooperate with Ras in MEF Transformation
Primary murine embryonic fibroblasts (MEFs) were sequentially infected with
a retroviral vector encoding H-RasV12 (Ras) and a retroviral vector encoding
Twist1, Twist2, or an empty vector (pBabe) as a control.
(A) Ras-infected cells underwent senescence, whereas Ras + Twist-infected
cells are immortalized.
(B) Foci formation assays indicating that Ras + Twist-infected MEFs have lost
cell contact inhibition. Foci numbers (for 33 103 cells) ± SD of triplicate exper-
iments are indicated.
(C) Ras + Twist-infected MEFs grow on soft agar. Colony numbers (for 23 105
cells) ± SD of triplicate experiments are indicated.
(D) MEFs infected with Ras alone or with Ras + Twist1 or Twist2 were subcu-
taneously grafted into irradiated Swiss nude mice. Ras + Twist-transformed
MEFs are tumorigenic. The number of mice developing tumors is indicated.
The tumors display characteristics of aggressiveness (including high mitotic
index and high vascular density).Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc. 83
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expression on Key Regulators of the p53
and Rb Signaling Pathways in Murine and
Human Cells
(A) Western blots of cell lysates. Ras, p16Ink4a,
ARF, p53, p21Cip1, Twist1, and Twist2 protein
levels are shown as indicated. Left panel: cell ly-
sates from uninfected (UI) MEFs, MEFs transiently
infected with a H-RasV12 (Ras) retroviral expres-
sion construct, and transformation assay-derived
cell lines coexpressing H-RasV12 and Twist1
(RT1) or H-RasV12 and Twist2 (RT2). ‘‘a’’ and ‘‘b’’
represent two independent infection experiments.
Right panel: cell lysates from uninfected MEFs or
from murine tumor-derived cell lines coexpressing
H-RasV12 and Twist1 or H-RasV12 and Twist2 as
indicated.
(B) Cell lysates from cell lines coexpressing H-
RasV12 and Twist1 infected with a shRNA directed
against the TWIST1 gene (shRNA TWIST1A) or the
luciferase gene (shRNA LUC). Inhibition of
TWIST1, as assessed by real-time qPCR (relative
mRNA levels are shown), is associated with the
restoration of p16Ink4a and p21Cip1 protein expres-
sion.
(C and D) Twist1 and Twist2 act as transcriptional
repressors of both p16INK4A and p21CIP1 genes.
E1A-immortalized MEFs were transiently cotrans-
fected with H-RasV12, p53, Twist1, and Twist2 ex-
pression constructs as indicated, along with the
human p21CIP1 (C) and p16INK4A (D) promoters.
Relative luciferase activity is shown.
Error bars represent mean ± SD of triplicate exper-
iments.shown in earlier studies (Yang et al., 2004), ectopic expression of
Twist1 alone in HMECs triggered several features of EMT (Fig-
ure 7). However, Twist1-mediated EMT was only partial as dem-
onstrated by the observed cellular morphology, the significant
but incomplete decrease of the E-cadherin epithelial marker,
and the modest increase of the vimentin mesenchymal marker
(Figures 7A and 7B). Of note, a similar effect was also observed
with Twist2. In contrast, expression of both Twist1 (or Twist2)
and H-RasV12 (or ErbB2) triggered a total loss of E-cadherin, an
increase in vimentin expression (Figure 7 and data not shown),
and a concomitant acquisition of invasive properties (Figure 7C).
A cooperative effect between Twist and mitogenic oncoproteins
on the acquisition of mesenchymal features and invasive pro-
perties was also observed in Ras-transformed mammary epithe-
lial MCF10A cells (MCF10A cells retrovirally infected by RasV12,
MCF10A pLX RasV12) (Figure S5) (Konishi et al., 2007).
Because the role of Twist1 in the induction of EMT was origi-
nally demonstrated in polarized Madin-Darby canine kidney
(MDCK) epithelial cells (Yang et al., 2004), we next examined
the effects of Twist1 or Twist2 in the presence or absence of
H-RasV12 in these cells. In line with previous observations, over-
expression of Twist1 or Twist2 alone was sufficient to trigger
some morphological features of EMT, including a fibroblastic
morphology, associated with a significant decrease of epithelial
markers and increase of mesenchymal protein levels. Neverthe-
less, as demonstrated by the additional reduction of epithelial
markers and further increase of mesenchymal protein expres-
sion, complete EMT required the presence of H-RasV12, confirm-84 Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc.ing the cooperative effect (Figure 8). The mechanisms underlying
this observation remain unknown. EMT is regulated by an
elaborate interplay of signaling pathways. However, it is note-
worthy that oncogenic Ras has been shown to cooperate with
TGF-b to induce EMT (Oft et al., 1996) and that TGF-b is believed
to act through the induction of several transcription repressors,
including Twist1 (Kang and Massague, 2004).
Taken together, our results highlight an unexpected double-
barreled oncogenic cooperation between Twist proteins and
mitogenic oncoproteins such as Ras and ErbB2. On one hand,
Twist1 or Twist2 allows cancer cells to override premature
senescence, and on the other hand, concomitant activation of
Twist and mitogenic signaling promotes complete EMT, thereby
facilitating invasion and metastasis.
DISCUSSION
Aberrant cell proliferation and malignant transformation induced
by some oncogenes are restrained by cellular senescence
(Serrano et al., 1997). First considered as a cell culture artifact,
premature senescence was recently confirmed in vivo as an
early barrier against tumor progression (Bartkova et al., 2005;
Chen et al., 2005; Gorgoulis et al., 2005; Collado et al., 2005).
Indeed, it occurs in many different precancerous tissues in
both humans and mice but is absent in malignant tumors, sug-
gesting that its inactivation is a general requirement for full-blown
cancer progression. However, the mechanisms allowing prema-
lignant cells to bypass this primary failsafe program remain
Cancer Cell
Inhibition of Premature Senescence by TwistFigure 7. Twist-Dependent Failsafe Program Escape in Human Mammary Epithelial Cells Is Associated with Complete EMT and Acquisition
of Invasive Properties
(A) Human mammary epithelial cells (HMECs) were infected with Twist1 or Twist2 retroviral expression constructs (left three columns) or sequentially infected with
ErbB2 and Twist1 or Twist2 retroviral expression constructs (right three columns) as indicated. First row: representative photomicrographs of SA-b-Gal staining.
Percentages of SA-b-Gal-positive cells (±SD of triplicate experiments) are indicated. Second row: phase-contrast microscopy showing cell morphology.
Percentages of fibroblastic cells (±SD of triplicate experiments) are indicated. Third and fourth rows: E-cadherin (epithelial marker) and vimentin (mesenchymal
marker) expression analysis by immunofluorescence. Nuclei were counterstained using Hoechst.
(B) Expression of E-cadherin and vimentin proteins in the same cells was analyzed by western blotting.
(C) Comparison by Matrigel invasion assay of the invasive properties of HMEC cells sequentially infected with ErbB2 and either Bmi-1 or Twist1 retroviral expres-
sion constructs as indicated. Bmi-1 was used as a control due to its ability to override oncogene-induced senescence.largely unknown. Our results show that Twist1 and Twist2, two
important regulators of embryogenesis, are frequently activated
in human cancer cells and that their induction is sufficient to
override oncogene-induced senescence in both murine and
human cells by inhibiting both the p53 and Rb tumor suppressor
pathways. In line with these observations, Twist proteins cooper-
ate with Ras to transform MEFs, further demonstrating their
oncogenic properties. At least in vitro, the Twist1 and Twist2 on-
cogenic activities appear to rely largely upon the inhibition of pre-
mature senescence. Indeed, in conditions where Ras activation
does not trigger senescence, e.g. targeted knockin of a mutant
K-Ras gene in immortalized MCF10A breast cells, no Twist-
dependent transforming activity as assessed by soft agar assay
(Figure S6) could be observed. Of note, MCF10A is a nontumori-
genic but immortal HMEC cell line displaying a rearrangement
and a deletion affecting the INK4/ARF locus that lead to a homo-
zygous loss of the p16INK4A, ARF, and p15INK4B genes (Cowell
et al., 2005).The role of Twist proteins in the inhibition of premature senes-
cence is concordant with previous studies that reported the
induction of Twist1 expression during the progression toward
malignant stages in several cancer types including prostate,
bladder, and pancreatic lesions (Kwok et al., 2005; Zhang
et al., 2007; Ohuchida et al., 2007). The inverse correlation be-
tween p16Ink4a and Twist1 protein levels in nevi and melanoma
samples also supports the role of Twist proteins as negative
modulators of p16INK4A and as crucial inhibitors of oncogene-
induced senescence in human cancer cells. As we have previ-
ously demonstrated that Twist1 and Twist2 are able to inhibit
Myc-induced apoptosis in vitro and in vivo (Maestro et al.,
1999; Valsesia-Wittmann et al., 2004), Twist proteins appear to
act as general inhibitors of oncogene-induced safeguard pro-
grams. Noticeably, in response to activated Ras, Twist1 and
Twist2 appear to act by downregulating the cyclin-dependent ki-
nase inhibitors p16Ink4a and p21Cip1 without affecting ARF levels,
whereas ARF is a crucial Twist target in response to aberrantCancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc. 85
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Inhibition of Premature Senescence by TwistFigure 8. Twist Proteins Cooperate with Ras to Induce Complete EMT in MDCK Cells
Madin-Darby canine kidney (MDCK) cells were infected with Twist1 or Twist2 retroviral expression constructs (left three columns) or sequentially infected with
H-RasV12 and Twist1 or Twist2 retroviral expression constructs (right three columns) as indicated.
(A) First row: representative photomicrographs of cells obtained by phase-contrast microscopy. Second and third rows: E-cadherin and vimentin expression
analysis by immunofluorescence. Nuclei were counterstained with Hoechst.
(B) Expression analysis of epithelial and mesenchymal markers, Twist1, Twist2, and Ras proteins by western blotting.Myc activation (Maestro et al., 1999; Valsesia-Wittmann et al.,
2004). Although the underlying mechanisms remain to be deter-
mined, the differential effect on ARF gene expression has been
confirmed in reporter assays (data not shown).
Escape from oncogene-induced senescence and apoptosis
being a general prerequisite for malignant conversion, our ob-
servations suggest that Twist1 and Twist2 are early drivers of
tumor progression and provide a rationale for the high fre-
quency of TWIST1 and TWIST2 overexpression in a large variety
of human tumors. Furthermore, these findings shed new light on
the role of Twist proteins in EMT and metastasis. Several
groups have previously reported that high Twist1 expression
promotes EMT and correlates with tumor invasion and meta-
stasis in a variety of human cancers (Yang et al., 2004; Miron-
chik et al., 2005; Kang and Massague, 2004). Overall, our
data show that in cells with aberrant mitogenic signaling,
Twist1 or Twist2 reactivation overrides primary safeguard
mechanisms to trigger cell transformation and, as a side effect,
promotes EMT in cooperation with mitogenic oncoproteins,
favoring invasiveness. In conditions where the mitogenic acti-
vation does not trigger senescence (due either to low levels86 Cancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc.of oncoprotein or to alternative mechanisms leading to a
deregulation of safeguard programs), Twist1 and Twist2 do
not display major transforming capabilities but still cooperate
with activated oncoproteins in promoting EMT (Figures S5
and S6).
A prevailing model proposes that transcription factors in-
volved in EMT promotion, such as Twist1, Snail, and Slug, are
induced in rare cancer cells residing at the invasive edge of
advanced carcinomas in response to signals released by the
activated stroma (Scheel et al., 2007). According to this model,
TWIST1 induction will not provide any growth advantage within
the primary tumor and will specifically favor cell dissemination,
particularly the steps of motility and invasiveness. Based on
our observations, we propose an alternative model in which, in
the presence of aberrant mitogenic signaling, reactivation of
the developmental proteins Twist1 and Twist2 promotes the
transition from a premalignant to a malignant stage by inactiva-
tion of innate failsafe programs. Due to the cooperative effect
of Twist1 or Twist2 and mitogenic factors on EMT promotion,
this model predicts that most of the cancer cells within the pri-
mary tumor will be responsive to EMT-inducing signals from
Cancer Cell
Inhibition of Premature Senescence by Twistthe microenvironment, highly increasing the risk of metastatic
dissemination.
Challenging the classical view of metastasis as the final step of
tumor progression, recent observations further support the no-
tion that early transformed cells are capable of dissemination.
Specifically, Klein and colleagues have reported that dissemi-
nated cancer cells in the bone marrow of breast cancer patients
exhibit different and fewer alterations than their matched primary
tumors (Schmidt-Kittler et al., 2003; Schardt et al., 2005). By
using BALB/c mice transgenic for the activated rat ErbB2/Neu
gene, the same group recently demonstrated that dissemination
of epithelial cells begins shortly after expression of the onco-
genic transgene, as early as the stage of atypical hyperplastic
lesion (Husemann et al., 2008). Strikingly, unlike both normal
mammary glands and the invasion front of advanced tumors,
these early lesions are characterized by a significant overexpres-
sion of TWIST1 (of note, TWIST2 expression was not examined
by these authors). Although further work is warranted to confirm
these observations in human cancers, these and our findings
support the hypothesis that reactivation of Twist proteins
in vivo promotes malignant conversion concomitantly with
metastatic dissemination.
EXPERIMENTAL PROCEDURES
Constructs
N-terminally FLAG-tagged human Twist1, Twist2, and H-RasV12 proteins were
expressed from the pBabe, pCI-neo, or pcDNA3 expression vectors (Prom-
ega). The human ERBB2 cDNA was subcloned into the pBabe retroviral
expression vector.
HumanARF, p16INK4A, and p21CIP1 luciferase reporter constructs have been
described previously (Linggi et al., 2002; Hara et al., 1996; el-Deiry et al., 1993).
The H-RasV12 pBabe and the Bmi-1 pBabe expression constructs were gener-
ous gifts from the laboratories of Robert A. Weinberg and Goberdhan P. Dimri.
shRNAs directed against the human TWIST1 gene (shRNA hTWIST1 A, 50-
GCTGAGCAAGATTCAGACC-30 [Yang et al., 2004]; shRNA hTWIST1 B, 50-
GTACATCGACTTCCTCTAC-30), the human TWIST2 gene (shRNA hTWIST2
A, 50-GCAAGAAGTCGAGCGAAGA-30; shRNA hTWIST2 B, 50-GCTGAGCAA
GATCCAGACG-30), and the murine TWIST2 gene (shRNA mTWIST2 A, 50-
GCAAGAAATCGAGCGAAGA-30; shRNA mTWIST2 B, 50-GCTCAGCAAGATC
CAGACG-30) and control shRNAs directed against the luciferase GL3 gene
(shRNA LUC, 50-CTTACGCTGAGTACTTCGA-30) and the prion pRpC protein
(shRNA PRPC, 50-TGAGCAGGCCCATCATACA-30) were subcloned into the
pRETRO-SUPER and the lentiviral pLVTHM expression vectors.
Cell Culture and Retroviral Infection
Primary MEFs (derived from C57BL/6 3 DBA2 F1 mice), E1A-immortalized
MEFs, transformed MEF cell lines, and tumor-derived cell lines were main-
tained in DMEM supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, 1 mM HEPES (GIBCO), and 0.1 mM nonessential amino acids.
RPMI 7951, T47D, MDCK, MCF10A, and HMEC cell lines were grown as rec-
ommended by the American Type Culture Collection (ATCC).
Plt-E and Plt-A producer cells were used to generate retroviral stocks. 3 3
106 Plt-E (-A) cells were transfected by calcium phosphate precipitation with
10 mg of retroviral vector and then placed after 24 hr in 5 ml of fresh medium
for viral production. Forty-eight hours after transfection, the supernatant was
collected, filtered (0.45 mm, Millipore), and supplemented with 4 mg/ml of poly-
brene (Sigma). The viral stock was placed in contact with 13 106 MEFs (or 2.53
105 human cells) for 3 hr, and infected cells were selected after 24 hr with
appropriate antibiotics. Cooperation assays were performed by sequential
infections using Ras- or ErbB2-expressing constructs and Twist1, Twist2, or
empty (pBabe) expression constructs, spaced by a 48 hr period of time.
Foci formation and growth on agar were assessed as described in Petrenko
et al. (2003). TWIST1 and/or TWIST2 depletion experiments were performedby a double 48 hr-spaced infection of cells with retroviral or lentiviral shRNA
expression virus using Plt-E or 293T cells as packaging cell lines.
Real-Time qRT-PCR
SYBR green quantitative PCR (Figure 1, Figure 2, Figure 3, and Figure 6)
was performed using 36B4 as an internal control gene. Trans-species primer
pairs were 50-GCAGGACGTGTCCAGCTC-30 and 50-CTGGCTCTTCCTCGCT
GTT-30 for TWIST1, 50-GCAAGAAGTCGAGCGAAGAT-30 and 50-GCTCTGCA
GCTCCTCGAA-30 for TWIST2, 50-GGCGGGGAATAAAACGGAGCGA-30 and
50-CCTCACGGGCACAAGTCTGGAA-30 for DEC1 (Collado et al., 2005),
and 50-GCTGATGGGCAAGAACACCA-30 and 50-CCGGATGTGAGGCAGCA
GTT-30 for 36B4.
The TaqMan quantitative PCR method used to analyze TWIST expression in
human primary tumors and tumor-derived cell lines is described in detail in the
Supplemental Experimental Procedures.
Human Tumor Samples
Human tissue samples were obtained from the Centre de Ressources Biologi-
ques (Centre Le´on Be´rard, French agreement number DC-2008-99) after
approval by the Comite´ de Protection des Personnes Lyon Est and by the
institutional review board and ethics committee of Centre Le´on Be´rard, with
fully informed patient consent.
Reporter Assays
3 3 105 E1A-immortalized MEFs were cotransfected with 1.5 mg of reporter
construct, 0.5 mg of expression vector, and 0.3 mg of internal pRL-TK-luc
construct (Promega) using jetPEI transfectant (Q-Biogen). Twenty-four hours
after transfection, luciferase activity was monitored using the Dual-Luciferase
Reporter Assay System (Promega) and a luminometer (Luminoskan Ascent,
Labsystem).
Mouse Xenografts
Animal maintenance and experiments were carried out in accordance with the
animal care guidelines of the European Union and with French laws and were
validated by the Comite´ Re´gional d’Ethique Animale CNRS Rhoˆne-Alpes. Six-
week-old female athymic Swiss nude mice (Charles River Laboratories) were
subcutaneously grafted in the left flank with 1 3 105 Ras + Twist1 or Twist2
retrovirally infected MEFs. Tumor growth was monitored twice a week with
calipers at the site of injection. Animals were allowed to form tumors up to
1.5 cm in diameter, at which point they were euthanized. Each tumor was
dissected and either fixed in formaldehyde and processed for histopathologic
examination or used for protein or RNA extraction.
Immunoblot Analysis
Cell lysates were prepared in RIPA buffer. Protein expression was examined
by western blotting using rabbit anti-mouse p16Ink4a M-156 and anti-human
p16Ink4a H-156 (Tebu-bio), anti-mouse p21Cip1 C-19 (Tebu-bio), anti-Ras
C-20 (Tebu-bio), anti-mouse ARF Ab80 (Abcam), anti-human ARF Ab1 (Neo-
Markers), anti-mouse p53 CM5 (Novocastra), and anti-Claudin-7 (Zymed)
polyclonal antibodies and mouse anti-human p21Cip1 SX118 (Dako), anti-b-ac-
tin AC15 (Sigma), anti-FLAG M2 (Stratagene), anti-E-cadherin, anti-N-cad-
herin, anti-a-catenin, anti-ZO-1 (BD Biosciences), anti-vimentin V9 (Dako),
and anti-occludin (Zymed) monoclonal antibodies for primary detection.
Horseradish peroxidase-conjugated donkey anti-rabbit or sheep anti-mouse
antibodies (Amersham) were used as secondary antibodies. Western blots
were revealed using an ECL Detection Kit (Amersham).
Characterization of Senescent Cells
SA-b-Galactosidase Staining
Cells were fixed in 3% formaldehyde, washed three times with PBS, and incu-
bated at 37C for 12 hr in buffer containing 40 mM sodium phosphate (pH 6),
5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 150 mM NaCl, 2 mM MgCl2, and 1 mg/ml
X-Gal.
Flow Cytometry Analysis
Trypsinized cells were washed in PBS, fixed in cold 70% ethanol/PBS for
30 min, washed, and incubated for 1 hr in 1 ml PBS containing 0.1 mg/ml
RNase A and 20 mg/ml propidium iodide. Cell-cycle profiles were thenCancer Cell 14, 79–89, July 2008 ª2008 Elsevier Inc. 87
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were analyzed using CellQuest software.
Immunofluorescence Analysis
Cells were seeded onto glass coverslips 24 hr prior to treatments. Cells were
fixed with 4% formaldehyde for 10 min, permeabilized with 0.1% Triton X-100
for 20 min at room temperature, saturated for 30 min with 10% FCS in PBS,
washed in PBS, incubated overnight at 4C with monoclonal anti-E-cadherin
(BD Biosciences) or anti-vimentin V9 (Dako) antibodies, and then incubated
for 1 hr with FITC- or TRITC-conjugated rabbit anti-mouse antibodies
(Dako). Cells were counterstained with 2 mg/ml Hoechst (33258, Sigma).
Coverslips were then mounted with Fluoromount-G (Southern Biotech).
Immunohistochemistry
Routine formalin-fixed and paraffin-embedded excision biopsies of a series of
melanocytic neoplasms (including 12 nevi and 10 melanomas) were analyzed.
Immunohistochemistry was performed on 5 mm tissue sections. All specimens
were immunostained with a non-biotin detection system (Bond Polymer Re-
fine, Leica Microsystems), with diaminobenzidine development. Heat-induced
antigen retrieval was performed using Tris-EDTA buffer (pH 9.0) in a water bath
at 95C for 30 min. Monoclonal anti-p16Ink4a (clone JC8, NeoMarkers) and anti-
Twist1 (clone Twist2C1a, Biomatrix) antibodies were used. Stainings were per-
formed with an automatic immunostainer (Bond System, Leica Microsystems).
Matrigel Invasion Assays
Matrigel (BD Biosciences) was added to the wells of an eight-well Labtek
chamber in a volume of 300 ml/well. A Matrigel plug of about 1 mm diameter
was removed. The hole was successively filed with 1 3 105 cells and 100 ml
of Matrigel. Appropriate growth medium was added on top. Cultures were
analyzed for up to 4 days. Areas of migration were visualized using an Olympus
IX50 (NA 0.075). Samples were performed in duplicate.
ACCESSION NUMBERS
Microarray data have been entered into the NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE11756.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, six figures, and one table and can be found with this
article online at http://www.cancercell.org/cgi/content/full/14/1/79/DC1/.
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